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Management of idiopathic glomerular disease associated
with nephrotic syndrome (INS) remains controversial and one
of the most complex areas relates to utilization of the drug
cyclosporin. This is despite its demonstrated effectiveness in
several histologic types of the INS in randomized controlled
trials. Cyclosporin is effective in inducing remission of
proteinuria in approximately 80% of steroid-sensitive cases of
minimal change disease (MCD). Cyclosporin is also effective
in both the induction of remission and long-term
preservation of renal function in steroid-dependent/-resistant
MCD and steroid-resistant focal segmental
glomerulosclerosis (FSGS). The overall response rate in FSGS
is lower than in MCD, and long-term therapy (412 months)
may be required to both achieve remission and sustain it.
Cyclosporin therapy is also of benefit in reducing proteinuria
in 70–80% of patients with steroid-resistant membranous
nephropathy (MGN). In MGN, the maximum benefit is often
delayed compared to MCD (412 weeks). Cyclosporin is
generally well tolerated and safe. The major concern remains
the nephrotoxicity, but with careful monitoring of the
patient’s renal function; minimizing the maintenance dose
and utilizing repeat renal biopsy in those receiving long-term
therapy, this risk can be minimized. The algorithms have
been developed derived from the best evidence in the
literature in each of the histologic types to help provide a
guide to the integration of cyclosporin into the management
of INS for the practicing nephrologist.
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Cyclosporin has been used in the treatment of idiopathic
glomerular disease associated with the nephrotic syndrome
(INS) in children and adults since 1985. Despite its proven
efficacy, there remains a lack of coherent guidelines to aid
clinicians in its use. An international workshop was convened
to address this issue and to undertake a multidisciplinary,
expert review of the clinical data currently available on
cyclosporin therapy in INS. The aims of the workshop were
(1) to examine where cyclosporin fits into the ‘therapeutic
armamentarium’; (2) to present a unified and integrated
approach for the use of cyclosporin in the most common
histologic variants of the INS, in both children and adults;
and (3) to provide recommendations for monitoring of
potential side-effects. The recommendations outlined are
proposed only as a guide, and are intended for use in
conjunction with the physician’s clinical judgment.
IDIOPATHIC NEPHROTIC SYNDROME—AN OVERVIEW
Nephrotic syndrome is defined as presence of heavy
proteinuria (X3.5 g day1 in adults; 440 mg m2 h1 or
41.0 g m2 day in children), hypoalbuminemia (o3.0 g dl1
in adults; o2.5 g dl1 in children), and edema. Hypercho-
lesterolemia is commonly present. Although there are many
known etiological agents that produce glomerular injury and
the features of the nephrotic syndrome, this workshop’s focus
was on primary glomerular disease of idiopathic cause.
The three leading histologic variants associated with the
INS are minimal change disease (MCD), focal segmental
glomerulosclerosis (FSGS), and membranous nephropathy
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(MGN). The relative frequencies of these histological
subtypes vary considerably according to the age at presenta-
tion and ethnicity.1,2 The causes of INS by definition remain
unknown but evidence exists that a primary T-cell disorder
may be responsible in MCD and FSGS. The first suggestion
that increased glomerular basement membrane permeability
was caused by a lymphokine was made more than 30 years
ago.3 Despite numerous studies, the identity of this
‘glomerular permeability factor’ remains elusive, but a host
of experimental observations propose a T-cell-driven circu-
lating factor that interferes with glomerular perm-selectivity
to albumin.4 The cause of idiopathic membranous nephro-
pathy remains equally elusive.
The nephrotic syndrome is associated with both renal and
extrarenal complications. It appears clinically that prolonged
nephrotic range proteinuria leads to renal scarring and
eventually renal failure although the5 precise mechanism of
how this occurs is unresolved.6,7 In adults it has been shown
that regardless of the underlying histology, patients with
proteinuria 43.8 g day1 had a 35% risk of end-stage renal
disease (ESRD) within 2 years, compared to only a 4% risk
for those with proteinuria o2.0 g day1.8 Added to the
concern of chronic renal failure is the observation that
hypoalbuminemia is associated with a poor prognosis in any
pathologic condition: a meta-analysis evaluating hypoalbu-
minemia and patient outcome found that a decrease of
1.0 g dl1 in serum albumin increased the odds of morbidity
by 89% and of mortality by 137%.9 In addition, patients with
nephrotic syndrome have an increased risk of thromboem-
bolism. Data from studies in MGN found the prevalence of
thrombotic complications to be 29% for renal vein
thrombosis, 17–28% for pulmonary embolism, and 11% for
deep vein thrombosis.10,11 In addition, the nephrotic
syndrome confers multiple risk factors for accelerated
coronary heart disease, including hypercholesterolemia,
hypertension, hypercoagulability, and exposure to certain
atherogenic drugs such as steroids. The risk of developing
coronary heart disease is four times greater in nephrotic
patients than in sex- and age-matched controls.12 Additional
complications in children with nephrotic syndrome include a
risk of serious infection, in particular cellulitis and sponta-
neous bacterial peritonitis.13 In summary, obtaining and
maintaining the lowest level of proteinuria when carefully
balanced by an awareness of the risks of therapy will result in
the best quality and quantity of both renal and patient
survival in this group of patients. See Table 1 for definition of
terms.
The duration and severity of proteinuria are known to be
surrogate markers of the progression of glomerular disease.
The main factor predicting the prognosis in all the histologic
variants of the INS is the response of proteinuria to
therapy.1,17–19 Therefore, the objectives of treatment are
threefold: (1) to lower proteinuria, (2) to reduce the
frequency of relapses of nephrotic syndrome, and (3) to
protect the kidney and prevent progression to renal failure.
CYCLOSPORIN—AN OVERVIEW
Cyclosporin is a peptide derived from the soil fungus
Tolypocladium inflatum gams. Following reports of its
immunosuppressive properties, first described in the early
1970s, cyclosporin was swiftly introduced as an anti-rejection
agent for organ transplantation. Cyclosporin is a calcineurin
inhibitor that suppresses the immune response by down-
regulating the transcription of various cytokine genes. The
most significant of these cytokines is interleukin-2 (IL-2),
which serves as the major activation factor for T-cells in
numerous immunological processes. Cyclosporin inhibits
cytokine production from T-helper cells (T-h1 and T-h2) and
also has an inhibitory effect on antigen-presenting cells
(Langerhans and dendritic cells), which are the main agents
of T-cell stimulation. A further effect of IL-2 inhibition is a
reduction in B-cell activation and subsequent antibody
production. IL-2 levels are known to increase during
proteinuria and to normalize during remission in adults
with the INS and in children with MCD or FSGS.20 However,
this pattern of IL-2 activity is felt to be part of a more wide-
spread disorder of cellular immunity that results in nephrotic
syndrome, rather than being causal of proteinuria.20
Table 1 | Definition of terms used in idiopathic nephrotic syndrome
Idiopathic NS definitions
Term Adult Pediatric14,15
Relapse Proteinuria X3.5 g day1 occurring after complete
remission has been obtained for 41 month
Albu-stix 3+ or proteinuria 440 mg m2 h1
occurring on 3 days within 1 week
Frequently relapsing 2+ relapses within 6 months 2+ relapses within 6 months
Complete remission Reduction of proteinuria top0.20 g day1 and serum
albumin 435 g l1
o4 mg m2 h1 on at least 3 occasions within 7 days
serum albumin 435 g l1
Partial remission Reduction of proteinuria to between 0.21 g day1
and 3.4 g day1 7 decrease in proteinuria of X50%
from baseline
Disappearance of edema. Increase in serum albumin
435 g l1 and persisting proteinuria 44 mg m2 h1
or 4100 mg m2 day1
Steroid-resistant Persistence of proteinuria despite prednisone therapy
1 mg kg1 day1 4 months
Persistence of proteinuria despite prednisone therapy
60 mg m2 4 weeksa
Steroid-dependent—NS recurs
when stop or decrease treatment
Two consecutive relapses occurring during therapy or
within 14 days of completing steroid therapy16
Two relapses of proteinuria within 14 days after
stopping or during alternate day steroid therapy
NS, nephrotic syndrome.
aOr persistence of proteinuria despite prednisone therapy 60 mg m2 4 weeks and three methylprednisolone pulses.
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Cyclosporin may also have an anti-proteinuric action
through an effect on glomerular permeability. This includes
an influence on perm selectivity, charge selectivity, and
glomerular filtration rate (GFR), supported by data from both
animal models and human studies21–27 that demonstrate
changes in proteinuria under conditions that have no known
immunologic causation. Furthermore, although cyclosporin
was found to reduce proteinuria, some studies have suggested
that the primary glomerular disease lesions may worsen despite
this reduction,22,23,28 hence the potential need for follow-up
renal biopsies during prolonged cyclosporin therapy.22
One of the main safety concerns of cyclosporin therapy is
its potential nephrotoxicity. This is a class effect common to
all calcineurin inhibitors, including tacrolimus29 and, there-
fore, needs regular monitoring of cyclosporin blood con-
centration as well as renal function are mandatory. Two
methods of measurement are available; trough blood levels
(C0 pre-dose concentration) or C2 levels (concentration at 2 h
post-dose). Trough level monitoring is common but does not
necessarily reflect cyclosporin exposure as a function of drug
intake. This may be better assessed by measuring the
concentration of cyclosporin 2 h after drug intake (C2).
30
The clinical benefits and target ranges for C2 monitoring in
idiopathic nephrotic syndrome patients are currently being
researched and preliminary published data have been
included in the relevant sections of this paper.31 Cyclosporin
can cause increased vascular resistance, resulting in reduced
renal blood flow, decreased clearance of endogenous
creatinine, and increased serum creatinine. Whether this is
the mechanism that leads to the chronic tubular interstitial
and vascular changes associated with chronic calcineurin
toxicity is unclear at present. Current recommendations
stipulate the reduction of cyclosporin dose if serum
creatinine increases by X30% above the patient’s baseline
value (even if this increase is within the normal range).32,33
Studies from the dermatology literature and non-renal organ
transplants have demonstrated that at least in the acute
situation these changes are functional and promptly reversed
following dose reduction or cessation of cyclosporin
therapy.34 Recent long-term studies support the contention
that with care the drug can be safely used for years in children
with the nephrotic syndrome and in renal transplant patients.
Using annual assessments of creatinine and creatine clear-
ance, stability of renal function has been shown for up to 20
years.35,36 In addition, recent research suggests better
monitoring tools using urinary biomarkers may soon provide
more sensitive, accessible, and safer indicators of cyclosporin
nephrotoxicity.37,38
The clinical efficacy and safety of once a day and pre-
prandial administration of cyclosporin in patients with
idiopathic nephrotic syndrome is currently being investi-
gated.31,39,40
CYCLOSPORIN BIOAVAILABILITY AND CLINICAL OUTCOME
Cyclosporin is a ‘critical-dose drug’: this means that a small
change in dose or plasma concentration may result in a
clinically significant change in efficacy and/or toxicity.
Individual drug dosing during cyclosporin therapy is
necessary because cyclosporin has a formulation-dependent
bioavailability and there is a wide interindividual variation in
cyclosporin absorption.
The Neorals formulation (Novartis Pharma AG, Basel,
Switzerland) of cyclosporin provides improved consistency in
drug delivery than the original Sandimmun formulation
(Novartis Pharma AG, Basel, Switzerland). In recent years,
generic manufacturers have introduced several new formula-
tions of cyclosporin. Many of these generic formulations have
shown considerable variation in pharmacokinetic parameters
and in the way in which patients react to each particular
drug. A patient who absorbs one cyclosporin formulation
satisfactorily, for example, will not necessarily absorb another
to the same degree, thus potentially either reducing efficacy
or increasing toxicity. This could have important conse-
quences if the brand of cyclosporin prescribed is swapped for
another brand (‘brand switching’), or if different brands are
given at the same time (‘partial switching’ or ‘brand mixing’).
If this is necessary because of costs or for other reasons, a
careful reassessment of the specific brand chosen must be
carried out to ensure similar blood concentrations of
cyclosporin are being achieved.
To address these problems, recommendations from several
national bodies, including the National Kidney Foundation
(USA) and the British National Formulary (UK), now state
that the prescribing physician should specify the exact brand
to be dispensed. Finally, patients should be consulted and
educated about generic drug substitution, so they are aware
of the potential implications and may alert clinicians if a
different formulation is unintentionally obtained.
DEVELOPMENT OF TREATMENT GUIDELINES AND ALGO-
RITHMS
Minimal change disease
Clinical background. Overview:41,42 MCD is the most
common cause of INS in children, accounting for more than
75% of all pediatric cases and for 90% of cases in children
under 5 years of age. In adults, MCD accounts for
approximately 20% of all cases of INS. The major
characteristic of MCD is the nephrotic syndrome, which
may be persistent or spontaneously remit and recur. The risk
of ESRD in MCD is extremely low, the only exceptions are
severe acute tubular necrosis associated with MCD seen in the
elderly and in people with pre-existing severe hypertension.
Treatment options: Corticosteroids are the first-line treat-
ment for MCD. Approximately 95% of children with MCD
achieve urinary remission of proteinuria within 4 weeks and
complete remission after an 8-week course of prednisone
(60 mg m2 day1 for four weeks followed by
40 mg m2 day1 on alternate days for 4 weeks). Increasing
the duration of corticosteroid therapy to a total of 12 weeks
improves the rate of sustained remission.43 Adults with MCD
generally receive lower doses of prednisone on a per kilogram
basis (1 mg kg1 day1 for 8 weeks), which may explain the
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lower remission rate of only 50–60%. However, an increase in
treatment duration (to 416 weeks) increases it to
B80%.44,45 Such a prolonged course of glucocorticoids,
however, entails an increased risk of steroid toxicity,
including glucose intolerance, cushingoid features, infections,
and hip osteonecrosis. Hip osteonecrosis is a particular risk
in elderly patients and post-menopausal women.
More than half of all patients who are initially steroid
responsive go on to experience relapses of their nephrotic
syndrome. Those who relapse frequently (Xtwo episodes
within 6 months) have a greater risk of becoming steroid-
dependent. Subsequent prolonged therapy with a corticoster-
oid is undesirable due to the potential of severe side effects
(as discussed above), and thus alternative therapies are
required in these patient subgroups, as well as in those who
are steroid-resistant.
In children, cyclophosphamide (2.0–2.5 mg kg1 day1)
given for 8–12 weeks or chlorambucil (0.2 mg kg1) given
for 8 weeks is usually well tolerated.13 Children with
frequently relapsing nephrotic syndrome appear to achieve
longer remissions with cytotoxic agents than those with
steroid dependency.46 Cytotoxic therapy is also effective in
steroid-sensitive adults; complete remission has been re-
ported in 81% of cases and partial remission in a further
8.5%.47 The disadvantage of cytotoxic therapy is the risk of
potentially severe adverse effects, specifically gonadal toxicity
and oncogenicity. In addition, since their toxicity is
cumulative, repeat courses of therapy carry increased risk
of these events. Mizoribine, an inhibitor of purine synthesis
developed in Japan, was reported to reduce the relapse rate in
children aged below 11 years, but had no significant
treatment effect when children of all ages were considered.48
Levamisole, an antihelmintic agent, has also been reported to
reduce relapses in children (dose used: 2.5 mg kg1 given on
alternate days),49 but did not show efficacy for more than 3
months after stopping treatment. Mycophenolic acid (MPA)
has induced stable remission in children and50 adults with
frequent relapses,51 but patient numbers were small and data
from larger scale randomized controlled trials are required.
Efficacy of cyclosporin in MCD: The articles selected for
inclusion here and in the FSGS and MGN sections have been
classified and subsequently graded by the authors according
to the level of evidence presented using the criteria described
by Carruthers et al.52 (Table 2).
The efficacy of cyclosporin in reducing the relapse rate in
steroid-dependent MCD in pediatric patients was described
almost 20 years ago.53 This has been confirmed in many
subsequent reports.
Level 1 evidence comes from the German study (APN NS
study VIII)54 (n¼ 104), which compared corticosteroid
monotherapy with corticosteroid/cyclosporin combination
therapy in children with their first manifestation of nephrotic
syndrome. The treatment arms consisted of prednisone
60 mg m2 day1 for 6 weeks, then reduced to 40 mg m2 48 h1
for a further 6 weeks, versus the combination of prednisone
(as described) plus cyclosporin at 150 mg m2 day1
commenced upon remission of proteinuria and given for
8 weeks. Children receiving prednisone monotherapy had
higher relapse rates during the first 12 months of follow-up
than those patients receiving cyclosporin combination
therapy. However, relapse rates in the two groups were
virtually equal by 24 months (50 versus 51.5%, respectively).
A benefit of cyclosporin combination therapy was observed
in children o7 years old and with a total serum protein
o44 g l1 at onset of disease (normal range: 66–87 g l1).
Level 2 evidence is provided by Tejani et al.,55 in a trial of
28 children with nephrotic syndrome randomized to receive
either cyclosporin and low-dose prednisone or high-dose
prednisone alone. Among 14 children receiving the combined
therapy, 13 entered remission versus only eight of 14
receiving prednisone alone.
Level 2 evidence is also provided by a study from the
French Society of Pediatric Nephrology, in which 40 children
with steroid-dependent MCD were randomized to receive
cyclosporin or chlorambucil.56 Cyclosporin was given at a
dose of 6 mg kg1 day1 for 12 weeks and then tapered off
over a further 12 weeks, while chlorambucil was given at
0.2 mg kg1 day1 for 40 days (cumulative dose 8 mg kg1).
Although good remission rates were achieved with both
treatments the relapse rate was higher in children receiving
cyclosporin, with relapses occurring during dose tapering and
within 6 months of drug cessation. The sustained remission
rate at 2 years was 5% for cyclosporin versus 45% for
chlorambucil.
Ponticelli et al.57 (Level 2) randomized 73 frequent
relapsers or steroid-dependent patients (31 with MCD;
remainder with FSGS), stratified by age into adults and
Table 2 | Levels of evidence for rating studies and grading
system for treatment recommendations52
Level Definition of evidence
1 Randomized controlled trial (RCT) that demonstrated a statistically
significant difference in at least one important outcome
OR
If the difference is not statistically significant, an RCT of adequate
sample size to exclude a 25% difference in relative risk with 80%
power, given the observed results
2 RCT that does not meet Level 1 criteria
3 Non-randomized trial with contemporaneous controls selected by
some systematic method (that is, not selected by perceived
suitability for one of the treatment options for individual patients)
OR
Subgroup analysis of a randomized trial
4 Before-after study or case series (of X10 patients) with historical
controls or controls drawn from other studies
5 Case series (of X10 patients) without controls
6 Case reports (of o10 patients)
GradingDefinition of recommendation
A Recommendation based on one or more studies at Level 1
B Best level of evidence available was at Level 2
C Best level of evidence available was at Level 3
D Best level of evidence available was lower than Level 3 and
included expert opinion
1432 Kidney International (2007) 72, 1429–1447
r e v i e w DC Cattran et al.: Cyclosporin in INS: treatment recommendations
children, to either cyclophosphamide (2.5 mg kg1 day1) for
8 weeks or full-dose cyclosporin (5.0 mg kg1 day1) for 9
months, followed by a 3-month taper off the drug. At 9
months, 64% (18/28) of patients on cyclophosphamide and
74% (26/35) of patients on cyclosporin entered remission
(P¼NS). However, after drug interruption many patients
who were given cyclosporin relapsed. At 2 years, 25% of
patients assigned to cyclosporin versus 63% of patients
assigned to cyclophosphamide were still in remission.
The remaining evidence for cyclosporin use in MCD is
Level 5. The long-term Collaborative Study of the French
Society of Nephrology included 112 patients.58 An update59
of this study comprises 150 adult patients with nephrotic
syndrome with either MCD or FSGS who had resisted
conventional therapy or, in the case of MCD, were steroid-
dependent or multi-relapsers. Eighty-six patients with MCD
were treated with cyclosporin (Sandimmun formulation) at a
dosage of 5.1870.94 mg /kg1 day1. Superior efficacy was
reported in steroid-dependent patients (complete remission
in 73% of cases and partial remission in 14%) compared to
those who were steroid-resistant (30 and 26%, respectively).
In addition, serum creatinine levels remained stable during
cyclosporin treatment (pretreatment: 91732 mmol l1, end-
point 98736 mmol l1; P¼NS). El Husseini et al.60 treated
117 children with idiopathic nephrotic syndrome for at least
2 years. The rate of complete remission was 82.1%, and
another 5.1% entered partial remission. Steroids were
stopped in 102 patients, of whom 31 relapsed. Out of 29
patients for whom cyclosporin was intentionally discontin-
ued while in remission, 22 relapsed. Six of these patients did
not respond to a second course of cyclosporin.
A sustained remission rate of 60% (24/40) was reported
following 1 year of continuous cyclosporin treatment in
children with steroid-dependent MCD.61 This study also
found that continuous cyclosporin therapy was more
effective than interrupted therapy in preventing relapses of
proteinuria (relapse rates of 56 versus 100%, respectively). In
addition, treatment interruptions appeared to diminish the
effectiveness of cyclosporin on reintroduction. Low-dose
cyclosporin monotherapy (Sandimmun formulation, mean
initial dose 2.4 mg kg1 day1) was used in a small study of
steroid-sensitive adults with MCD.62 Eight of the 11 patients
(73%) promptly entered complete remission after mean
treatment duration of 44 days, and the remaining three
patients achieved complete remission when cyclosporin was
combined with corticosteroid pulse therapy. There were no
significant changes in creatinine clearance or blood pressure
during the study period. Lastly, remission occurred in five
out of six (83%) children with MCD treated with cyclosporin
(starting dose 6 mg kg1 day1 given for a maximum of 6
months) in a study of refractory nephrotic syndrome63 (see
also Table 3 for a summary of study details).
Remission of proteinuria in MCD usually happened
within the first 3 months of treatment and was maintained
with cyclosporin; however, relapse occurred when the drug
dose was reduced or stopped.64
The rapid recurrence of nephrotic syndrome following
cessation of cyclosporin therapy led to the concept of
‘cyclosporin dependency,’ and the prospect of indefinite
patient exposure to a potentially nephrotoxic drug.59 A
subsequent analysis of the Collaborative French study data22
revealed that patients who escaped ‘cyclosporin dependency’
had a longer duration of uninterrupted treatment (27.2722
months) than those who were cyclosporin-dependent
(6.7574.2 months). Gradual tapering of drug dose also
seemed an additional factor characterizing patients with
durable remission, suggesting that stopping treatment abruptly
induced relapse in the form of a ‘rebound effect.’ Moreover, in
adult patients whose remission still depended on cyclosporin,
control of proteinuria could be maintained with a low dose of
cyclosporin (on the order of 1–3 mg kg1 day1), significantly
below the usual toxic range.22,62
Tolerability of cyclosporin in MCD: Data from APN NS
study VIII concluded that cyclosporin-associated side effects
in children were mild and reversible.54 The Collaborative
French Society of Nephrology study59 demonstrated good
tolerability in adults, with only 10% of patients reporting side
effects that led to stopping treatment. Furthermore, there was
no increased risk of bacterial/viral infection and the risk of
malignancy was considered to be virtually nil. In the study of
El Husseini et al.,60 hypertension occurred in 10% of patients,
and 6% of patients had an increase in serum creatinine
430%. Post-therapy biopsies, performed in 45 patients,
showed mild stripe interstitial fibrosis and tubular atrophy in
two patients (4.4%). At the last follow-up, one child had
developed end-stage renal failure and two had chronic renal
insufficiency. Duration of cyclosporin therapy (using San-
dimmun formulation at B3 mg kg1 day1) (424 months)
and duration of heavy proteinuria (430 days) not typical of
steroid-dependent MCD in children were identified as risk
factors for cyclosporin-induced tubulointerstitial lesions in
children with MCD.65
These findings,60,65 coupled with lack of correlation
between GFR and severity of histological changes,22,66,67
suggest repeat renal biopsies in children receiving long-term
(that is, 42 years) cyclosporin therapy should be considered.
Treatment guidelines and algorithm for use of cyclosporin
in minimal change disease (for children). Who to treat?
Cyclosporin is recommended for children who are steroid-
dependent following multiple relapses or who have unac-
ceptable steroid toxicity (Figure 1).
When to treat? Cyclosporin should be used in children
who remain steroid-dependent despite a course of cytotoxic
therapy [Grade B],68 or where cytotoxic therapy is contra-
indicated and in children who develop steroid toxicity.
Cyclosporin should be commenced after achieving complete
remission of proteinuria with prednisone. In the rare case of
steroid-resistant MCD in children defined by persistence of
proteinuria beyond 28 days of prednisone treatment,
cyclosporin may be considered [Grade D].
How to treat? Cyclosporin should be given at the smallest
effective dose using a twice daily (b.i.d.) dosing regimen
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Table 3 | Cyclosporin studies in minimal change nephropathy
Reference Study design Subjects Treatment Results
Levesl 1 and 2
Hoyer54 Multicenter, randomized,
controlled
n=55 Pred alone Pred 60 mg m2 day1 6 weeks
then 40 mg m2 per 48 h 6 weeks
CsA+Pred group had lower relapse
rates at months +6, +12 (10 and




n=49 CsA+Pred Same Pred scheme then CsA
150 mg m2 day1 given on
remission 8 weeks
Relapse rates for both groups
similar by +24 months (51.5%
CsA+Pred versus 50% Pred alone)
Pred alone versus CsA+Pred
Niaudet56 Multicenter, randomized,
controlled
n=20 CsA CsA 6 mg kg1 body weight per day
in two divided doses 3 months;
dose then tapered over next 3
months
CsA allowed Pred withdrawal in 18/
20 patients; 17 of whom relapsed





n=20 Chlorambucil Chlorambucil 0.2 mg kg1 body
weight per day 40 days (C/D
8 mg kg1 body weight)
Chlorambucil allowed Pred
withdrawal in 16/20 patients; 10 of
whom relapsed within 34 months
of drug D/C
CsA versus Chlorambucil Pred given at 30–60 mg m2 day1,
then on alternate days following
cessation of proteinuria
Relapse rate at 2 years 5% CsA
versus 45% Chlorambucil




Chlorambucil group: no short-term
toxicity, no leucopenia
Tejani55 Randomized, controlled n=14 Pred alone Pred 60 mg m2 day1 4 weeks
then 40 mg m2 per 48 h 4 weeks
Remission in 13/14 from
combination group versus 8/14
from Pred group (Po0.05)
Children with onset of
NSo1 year
n=14 CsA+Pred CsA 7 mg kg1 body weight per
day+Pred 20 mg m2 day1 4
weeks then Pred reduced to
10 mg m2 day1 for next 4 weeks
No difference in duration of
remission between two groups
Pred alone versus CsA+Pred
Ponticelli57 Randomized, controlled n=18 CsA CsA 5 mg kg1 day1 adults or
6 mg kg1 day1 children 9
months; dose then tapered by 25%
per month and discontinued at 12
months
Results data include MCD and FSGS
cases
Adults and children with
steroid-dependent,





2.5 mg kg1 day1 8 weeks
At month 9: CR in 26/35 and PR in
5/35 CsA group versus CR in 18/28
and PR 1/28 Cyclophosphamide
group; P=NS
At year 2: 25% CsA group versus
68% Cyclophosphamide group in
remission
Tolerability to both drugs was
good; CsA-related side effects were





n=86 refractory MCD CsA (Sandimmun formulation)
5.1870.94 mg kg1 day1
CR in 73% of cases and PR in 14%
compared to those who were




Serum creatinine levels remained
stable during CsA treatment
(pretreatment: 91732mmol l1,
endpoint 98736mmol l1; P=NS).
Hulton61 Single-center, uncontrolled n=40 Phase 1 (of
whom 27 entered
into Phase 2)
Phase 1: CsA 5 mg kg1 day1 given
twice daily 1 year
Phase 1: relapse rate 40% (16/40)
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[Grade B]. The dose should be started at 100 mg m2 day1
(given in two divided doses) and may be increased to
150 mg m2 day1.
What to target? Treatment targets include complete or
partial remission of proteinuria, preservation of stable GFR
(720% of pretreatment level), and a C0 cyclosporin level of
80–120 ng ml1.
When to stop treatment? There is little data in the literature
that focuses on treatment duration; however, renal function
and previous clinical course should serve as a guide; for
example, estimation of creatinine clearance via the Cock-
croft-Gault equation or other appropriate formula (Schwartz
formula for children, modified MDRD formula in adults, and
so on). In the steroid-resistant or -dependent cases following
complete remission of proteinuria, cyclosporin should be
continued for 1-2 years and then tapered gradually to lowest
effective dose. Data suggest that continuous therapy is more
effective than interrupted therapy in preventing relapses of pro-
teinuria and in addition treatment interruptions appear to
diminish the effectiveness of cyclosporin on reintroduction.61
Children continuing on long-term cyclosporin therapy
should be regularly monitored, including a renal biopsy every
2-3 years to check for histological evidence of nephrotoxicity.
The use of alternative drugs therapy should be considered
(for example, cytotoxic agents or MPA) in children
who remain steroid- and/or cyclosporin-dependent despite
long-term cyclosporin therapy. Comparative studies using
these medications are underway. In children who are non-
responsive to corticosteroids, cyclosporin should be given for
at least 6 months before considering the treatment a failure.
Treatment of adults with MCD is essentially similar to that
in children—see Figure 2 (adults).
Who to treat? Adults with MCD should initially be treated
with corticosteroids for a minimum duration of 12–16 weeks.
Cyclosporin is recommended for adults who are steroid- or
steroid-dependent, or in a patient with steroid toxicity or in
whom steroids are contraindicated (a rare but possible
example of this is the pregnant woman with MCD or FSGS.
High-dosage corticosteroids are hazardous to the mother and
the fetus. Conversely, it has been established that cyclosporin
is less harmful to the fetus and may control the nephrotic
syndrome).69
When to treat? In adult patients experiencing multiple
relapses, cyclosporin therapy should be tried after a 12-week
course of cyclophosphamide has either failed or not
produced a durable remission. It seems advisable to wait
until the leukocyte counts have returned to normal before
cyclosporin replaces cytotoxic therapy to avoid the added
risks of combined/overlapping immunosuppression.
How to treat? In adults, cyclosporin should be commenced at
a dose of 2 mg1 kg1 day1 and gradually increased at 2-week
intervals until remission is achieved or the dose is
Table 3 | Continued
Reference Study design Subjects Treatment Results
Children with steroid-
dependent MCD
Pred also given (X1 mg kg1 per
48 h) as tapering dose and then
stopped within first 8 weeks of CsA
therapy
Phase 2: relapse rate 56% (10/18)
group A versus 100% (9/9) group B
Long-term CsA therapy Phase 2: Continuous CsA therapy
(group A; n=18) versus Interrupted
CsA therapy (group B; n=9); CsA
treatment duration X1 year
Long-term Pred required to
maintain remission in 40% (16/40)
Serum creatinine remained stable
and did not differ between groups,
13/40 (32% had hirsuitism, 8/40
(20%) had gum hypertrophy
Matsumoto62 Single-center, uncontrolled n=11 CsA 2.4 (range: 1.5–3.1)
mg kg1 day1 in two divided
doses—given until CR of
proteinuria achieved
CR in 8/11 (73%) after mean
duration of 44 days (731 days)
Adults with MCD CR in remaining three patients
achieved following addition of Pred
Low-dose CsA monotherapy Initial non-responders had higher
levels of serum cholesterol
No significant changes in serum
creatinine or blood pressure
Singh63 Single-center, uncontrolled n=6 MCD CsA 6 mg kg1 day1 given until CR
achieved
Response observed in 5/6 (83%)
Children with refractory NS Maximum treatment duration 6
months
No specific tolerability issues
described for MCD cohort
CsA in NS
CsA, cyclosporin; C/D, cumulative dose; CR, complete remission; D/C, discontinuation; INS, idiopathic nephrotic syndrome; MCD, minimal change nephropathy; NS, nephrotic
syndrome; Pred, prednisone.
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5 mg kg1 day1 or toxicity occurs. Following 3 months of
stable remission, the dose should be very slowly and pro-
gressively tapered to reach the minimum dosage that maintains
remission. If non-nephrotic proteinuria reappears the dose of
cyclosporin should be increased for one to two months until
remission is achieved [Grade D]. The dose should then be
tapered as before [Grade D]. It is the author’s (AM) experience
that in most cases remission can be sustained with cyclosporin
alone, although a few cases may require low-dose prednisone
for treatment of relapse despite cyclosporin treatment.
What to target? Treatment targets for adults are the same
as the pediatric age group.
When to stop treatment? Following complete remission of
proteinuria, cyclosporin therapy should continue for 1-2
years, during which time the dose should be tapered
gradually and maintained at a minimum dose target of
p2 mg kg1 day1. The acquired experience22 indicates that
in most cases of MCD the renal toxicity of cyclosporin is low,
characterized by a few stripes of interstitial fibrosis. Adults
continuing on long-term cyclosporin therapy should be
regularly monitored, including consideration of repeat renal
biopsy at 12–24 months to check for histological evidence of
nephrotoxicity, especially if serum creatinine is 430% above
the baseline level, and/or if the maintenance dose of
cyclosporin required is 43.5 mg kg1 day1 [Grade D].
If an adult remains non-responsive to cyclosporin after 6
months of therapy, it should be stopped; a repeat renal biopsy
carried out to confirm or refute the initial diagnosis.
Depending on the results symptomatic treatment or alter-
native forms of therapy should be considered [Grade C].
FSGS (nephrotic)
Clinical background. Overview: FSGS in all age groups,
accounting for 7–20% of nephrotic syndrome cases in
children and a significant higher percentage in adults.1 FSGS
is observed more frequently in Afro-Caribbean patients than
in Caucasians, with prevalence as high as 80% among
nephrotic patients.1 If untreated, more than 50% of patients
with persistent nephrotic syndrome will progress to ESRD
within 5-10 years.1 Remission of proteinuria is the only
significant predictor of renal survival in FSGS and indicates a
reduced likelihood of progression to ESRD.19 Spontaneous
remission of proteinuria in FSGS is uncommon (o6% cases),
emphasizing the importance of trying to achieve remission
using drug treatment. Recent advances in the genetics of
FSGS have altered the understanding of this group of
diseases, in which the histologic picture is the common
denominator rather than a specific etiological agent. Genes
specific for podocyte structures or signaling have been
demonstrated to be responsible for the FSGS lesion and the
Corticosteroid therapy
Responder (~95%)
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Remission
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monitor, including renal
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Steroid-dependent




Consider use of prednisone
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Figure 1 | Algorithm for the use of cyclosporin in the treatment of minimal change disease in children.
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proteinuria (WT1,70 NPHS2,71 CD2AP,72 ACTN4,73 and
TRPC674,75). The specific incidence of genetic mutations
producing the FSGS lesions is unknown although it is
significantly higher in children than in adults. The variability
of these mutations in terms of their clinical phenotype and
whether their presence negates the need for immunosup-
pressive therapy remain unanswered questions.76
Treatment options: The specific treatment of FSGS patients
with the nephrotic syndrome is controversial. Very few
randomized controlled trials have been made. Meta-analysis
in adults, in general, shows a good response to corticosteroids
alone in FSGS with complete remission rates ranging from 30
to 60% and partial remission rates in up to an additional
30%. The remaining 40–50% show no response.77 Prolonged
steroid treatment (up to 6 months) is associated with a
higher complete remission rate but is accompanied by more
frequent complications, and many patients, especially in the
older age group, the obese, and those with other co-morbid
conditions cannot tolerate long or repeated exposure to this
duration of steroid treatment. The best prognostic indicator
remains a complete remission of proteinuria to corticosteroid
therapy,77 although recent data also confirm the clinical
importance of a partial remission on long-term outcome.19
Cytotoxic agents can attain good remission rates in
steroid-sensitive FSGS, with complete remission in 51% of
cases and partial remission in a further 23%.78 The reasons
for initiating cytotoxic agents in FSGS are similar to those for
their use in steroid-sensitive MCD. However, their chance of
attaining remission in steroid-resistant FSGS is low. The most
optimistic retrospective study (Levels 4 and 5), reported an
overall remission rate of only 17% for complete remission
and 7% for partial remission in adults and 52 and 17% for
complete and partial remission in children.79 A more
pessimistic retrospective review80 reported no benefit with
cyclophosphamide (2.5 mg kg1 day1).
A recent meta-analysis of randomized controlled trials in
pediatric nephrotic syndrome81 showed no significant
difference in complete remission in children with FSGS
treated with oral cyclophosphamide plus prednisone versus
prednisone alone (one trial, n¼ 53; RR 1.01; 95% confidence
interval 0.75–1.47). The general opinion is that cytotoxic
agents do not increase the chances of remission in steroid-
resistant FSGS but may prolong its duration.64
Efficacy of cyclosporin in FSGS: Level 1 evidence is
presented by Cattran’s study,82 in which a 26-week regimen
of cyclosporin therapy was compared with placebo in 49
adult patients with steroid-resistant FSGS; both groups
received low-dose prednisone. Cyclosporin was given at
3.5 mg kg1 day1 in two divided doses for 26 weeks; the drug
dose was tapered over the next 4 weeks and then stopped. All
patients received prednisone at 0.15 mg kg1 day1 for 26
weeks, which was then tapered over the next 8 weeks. Patients
were followed up for an average of 200 weeks. By week 26,
partial or complete remission of proteinuria had occurred in
70% of the treatment group versus only 4% of the placebo
group (Po0.001). Relapse after stopping cyclosporin
Full-dose corticosteroid
Initial renal biopsy shows
minimal change nephropathy
(MCD)











Consider renal biopsy to
verify diagnosis of MCD
Continue with low-dose corticosteroid
and add cyclosporinCyclophosphamide







No remission after 6 months
at a non-toxic doseStop corticosteroids
Monthly dipstick 
surveillance to detect 
possible relapse requiring
short course of steroid 
Stop cyclosporin 
Give symptomatic treatment
Consider MPATaper corticosteroids to a minimum dose
Keep on cyclosporin for ~2 years and taper to 
a minumum dose controlling proteinuria
Continue to monitor renal function.
Consider renal biopsy at 12–18 months
Figure 2 | Algorithm for the use of cyclosporin in the treatment of minimal change disease in adults.
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occurred in 40% of those patients achieving remission by 52
weeks and in a further 20% by week 78, with the remainder
continuing in remission to the end of the observation period.
In addition, long-term renal function was significantly better
preserved in the cyclosporin group; approximately 50% of
the placebo group had doubled their serum creatinine level
compared with only 25% in the cyclosporin group. This is an
important finding in a group of patients at high risk of
developing ESRD.
Further Level 1 evidence is provided by Ponticelli et al.83
Cyclosporin was compared to symptomatic treatment in 44
patients (adults and children) with steroid-resistant nephro-
tic syndrome.83 Only 28/44 patients had biopsy-proven
FSGS; 10 adults and 4 children received cyclosporin and 9
adults and 5 children received standard therapy. The treat-
ment group received the Sandimmun formulation of cyclo-
sporin at 5 mg kg1 day1 for adults and 6 mg kg1 day1 for
children in two divided doses for 6 months; the drug dose
was then tapered off to 0 over the next 6 months. Eight
(57%) cyclosporin-treated patients attained remission (com-
plete or partial). Three (16%) control patients had partial
remissions but incomplete details regarding their diagnoses
were given (that is, FSGS and MCD cases were combined).
Most remissions occurred within the first 4 weeks; however,
the majority of remitters had relapsed by the end of month 12
when cyclosporin was stopped. Specific data for FSGS
patients were not presented.
The German glomerulonephritis study group achieved full
remission with steroids and cyclosporin in 23% of patients
and partial remission in a further 38%. Additional treatment
with chlorambucil was found to be ineffective in adult
patients with FSGS84 (Level 2).
A retrospective analysis of adults with FSGS demonstrated
that prolonged treatment with cyclosporin (448 months) is
required to achieve complete remission in some patients85
(Level 4).
Cyclosporin therapy (3.0 mg kg1 day1 given in two
divided doses) significantly reduced levels of proteinuria in
a 6-month randomized controlled trial of 25 children with
steroid-resistant FSGS (Level 1).86 Proteinuria decreased
from 151.7 (7162.4) to 36.9 (742.3) mg kg1 day1 over
the study period (Po0.05). In addition, hypercholesterole-
mia was found to be associated with a reduced therapeutic
effect of cyclosporin. Remission occurred in 25/42 (60%)
children with refractory FSGS treated with cyclosporin
(starting dose 6 mg kg1 day1 given for a maximum of 6
months) (Level 5).63
An overview of retrospective studies in adults and children
with FSGS indicated that 40–50% of cases can be maintained
in remission of proteinuria with cyclosporin.64 Most of these
patients were steroid-resistant, and a better response was
observed in those who were steroid-sensitive (see also Table 4
for a summary of study details).
Tolerability of cyclosporin in FSGS: The risk of adverse
effects with cyclosporin in FSGS is comparable to that
reported in MCD.58 However, concern has been expressed
regarding the potential nephrotoxicity of cyclosporin and the
possible acceleration of this particular type of renal disease.
The data suggest that the risk of cyclosporin nephropathy is
low if guidelines are followed and patients are monitored
regularly.64 Other safety data are shown in Table 4.
Treatment guidelines and algorithm for use of cyclosporin in
FSGS (nephrotic) in children. See Figure 3 for full details.
Who to treat? According to pediatric recommendations,
patients usually undergo a kidney biopsy when remission
cannot be achieved after 4 weeks of prednisone at
60 mg m2 day1 (steroid resistant). In a case of a diagnosis
of FSGS, cyclosporin treatment should be considered as a
treatment option.
When to treat? Children with persistent nephrotic range
proteinuria 41 g m2 day1 despite 4 weeks of daily
corticosteroid therapy. (The French Pediatric Nephrology
Society approach recommends three pulses of methylpredni-
solone before the condition is called ‘steroid-resistant.’). If the
corticosteroid treatment is well tolerated, a further 4 weeks of
therapy should be considered prior to initiating new therapy
since the response rate will increase an additional 10–20%.
The emerging knowledge of different gene mutations
associated with FSGS may tailor the therapeutic ap-
proach—see Figure 3.
How to use? Cyclosporin should be started at a moderate
dose (100 mg m2 day1 given in two divided doses) and
gradually increased to a maximum of 150 mg m2 day1,
depending on the effect on proteinuria (upper dose limits
have not yet been defined, but an increasing risk for
nephrotoxicity is expected above this dose level). Long-term
treatment is usually required to obtain remission [Grade A].
All published studies show a benefit with cyclosporin therapy
only if it is combined with alternate day prednisone for the
first 6 months (30 mg m2 per 48 h for 6 months or
40 mg m2 per 48 h for 2 months followed by 30 mg m2 per
48 h for 2 months followed by 20 mg m2 per 48 h for 2
months).
What to target? Treatment targets include complete or
partial remission of proteinuria, preservation of glomerular
filtration rate (720%), and a cyclosporin C0 blood level of
o150 ng ml1. Individual experience [Grade D] suggests
short-term higher levels may be of benefit,87 but further
evidence for this is lacking in the literature. A small study by
Mitsoni et al.88 suggest that C2 appears to be a better
predictor of AUC than C0 in children with INS; however,
targets using C2 levels have not yet been defined.
When should renal biopsy be carried out? Repeat biopsies
should be carried out in a patient with rapidly declining renal
function, a marked disparity between an increasing serum
creatinine and decreasing proteinuria and in patients
receiving cyclosporin therapy beyond 2-3 years. The presence
of increasing fibrosis and tubular interstitial disease should
lead to a careful review of the case. It is often difficult to
differentiate between drug toxicity and the natural history of
the FSGS disease and hence the decision between lowering or
discontinuing medication and/or adding adjunctive therapy
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Table 4 | Cyclosporin studies in focal segmental glomerulosclerosis (nephrotic)
Reference Study design Subjects Treatment Results
Levels 1 and 2
Cattran82 Multicenter, randomized,
controlled
n=26 CsA CsA 3.5 mg kg1 day1 given in two
divided doses 26 weeks, then
tapered to zero over 4 weeks
PR or CR in 70% (18/26) CsA group versus




n=23 Placebo All patients received Pred
0.15 mg kg1 day1 26 weeks, then
tapered over 8 eight weeks
CsA group: Relapse occurred in 40% of
remitters by week 52 and in 60% by week
78; remainder stayed in remission until end
of study period (Bweek 200)
CsA versus Placebo 50% decrease in baseline creatinine
clearance observed in 25% CsA group
versus 52% of Placebo group (Po0.05)
No significant difference in cases of
hypertension between treatment groups
CsA group: n=1 case of gastrointestinal
symptoms requiring drug D/C
Ponticelli83 Multicenter, randomized,
controlled
FSGS adults: CsA adult dose 5 mg kg1 day1 or
pediatric dose 6 mg kg1 day1 6
months, then tapered by 25% every 2
months until D/C
PR or CR in 57% CsA group (6/10 adults
and 2/4 children) versus 16%a Control
group (3/19a) (Po0.001)
Children and adults with
steroid-resistant INS
(FSGS+MCD)
n=10 CsA Supportive therapy 12 months;
corticosteroids and
immunosuppressants not permitted
CsA group: Remission occurred within first
4 weeks of treatment; 70%a of remitters
had relapsed by month 12
CsA versus supportive
therapy
n=9 Controls Incidence of infection and hypertension
similar for both groups
FSGS children: CsA group: Gum hypertrophy and
hypertrichosis frequent but all cases
reversed upon drug D/C
n=4 CsA
n=5 controls Corticosteroid rescue therapy allowed




n=12 CsA CsA 3 mg kg1 day1 given in two
divided doses 6 months
Reduction in proteinuria in 12/12 CsA
group versus 2/12 placebo group
Children with steroid-
resistant FSGS
n=12 Placebo Vehicle control CsA induced significant reduction in




n=34 CsA Steroids 1.5 mg kg1 day1 and CsA
adult dose 5mg kg1 day1 versus




n=23 Chlorambucil Steroids 1.5 mg kg1 day1 and
Chlorambucil (0.1–0.4 mg kg1 day1)
6–12 weeks followed by CsA
CsA versus Chlorambucil
followed by CsA
Levels 4 and 5
Singh63 Single-center,
uncontrolled
n=42 with FSGS CsA 6 mg kg1 day1 given until CR
achieved
Response observed in 25/42 (60%)
Children with refractory
NS
Maximum treatment duration 6 months Hypertension in 45% patients; gum
hypertrophy, hirsutism and hypertrichosis
common on higher CsA doses; no cases of
infection
CsA in NS CsA-induced nephropathy: ‘severe’ lesions
in 50% patients on renal biopsy (all
patients treated with CsA412 months)
Alexopoulos85 Retrospective case
analysis
n=33 FSGS of whom
n=17 had NS
n=11 patients received Pred (1 mg kg1
for at least 1 month); those with partial/
no response were also given CsA
(2–3 mg kg1 for average of 25 months)
64% remission with Pred alone after 6–12
months treatment
Adults with FSGS A further 6 patients received
symptomatic therapy only
CR in 28% and PR in 54% of those
requiring additional CsA (at end of follow-
up; mean duration 57 months)
CsA, cyclosporin; CR, complete remission; D/C, discontinuation; FSGS, focal segmental glomerulosclerosis; INS, idiopathic nephrotic syndrome; MCD, minimal change
nephropathy; NS, nephrotic syndrome; PR, partial remission; Pred, predisone.
aData include cases of FSGS+MCD cases.
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remains a balance between the patient’s clinical course/
response or the observed histologic changes.
When to stop treatment? Renal function (GFR) serves as a
guide more than renal histology. Following complete
remission of proteinuria, cyclosporin should be slowly
tapered (by 0.5 mg kg1 month1) to a minimum effective
dose and then maintained for 1-2 years. Rapid deterioration
of renal functional may occur even after years of continuous
treatment when the cyclosporin is stopped.
If no response to cyclosporin has occurred after 6 months
of treatment (a minimum would be a 50% reduction in
baseline proteinuria), other symptomatic treatment should
be considered.
Treatment guidelines and algorithm for use of cyclosporin
in FSGS (nephrotic) in adults. Who to treat? Patients
should initially be treated with conservative therapy to
normalize blood pressure and LDL cholesterol using ACE
inhibitors7ARB therapy, diuretics, statins, and so on).
Patients should also be carefully monitored for signs of any
deterioration in renal function. Corticosteroid therapy
(1 mg kg1 day1 for 8–16 weeks) should be commenced
when maximum conservative therapy fails to lower protei-
nuria to o3 g day1. Cyclosporin should be given to patients
who become steroid-dependent or who are steroid-resistant
[Grade A]. Cyclosporin therapy is also appropriate in
patients with steroid toxicity or in whom steroids are
contraindicated (Figure 4).
When to treat? Patients with persistent proteinuria
43 g day1 despite corticosteroid therapy. In adults who do
not achieve at least a partial remission by 8 weeks of daily
prednisone and/or those who have unacceptable adverse
steroid effects.
How to use? Cyclosporin should be started at low dose
(2 mg kg1 day1 in two divided doses) and gradually
increased to a maximum of 4 mg kg1 day1, depending on
the effect on proteinuria; the dose should not exceed
5 mg kg1 day1. In light of careful pharmacokinetic mon-
itoring one could adapt the dose (see ‘what to target’). Long-
term treatment is usually required to achieve the maximum
benefit (46–12 months) [Grade B].
What to target? Treatment targets include complete or
partial remission of proteinuria, preservation of glomerular
filtration rate (720%), and a cyclosporin level—
C0¼ 125–175 ng ml1 and C2o500 ng ml1.
When to stop treatment? Renal function (GFR) serves as a
guide. Following complete remission of proteinuria, cyclos-
porin should be slowly tapered (by 0.5 mg kg1 month1) to
a minimum effective dose and then maintained for 1-2 years.
In patients with steroid dependency, corticosteroid should
also slowly be tapered to a minimum effective dose or
Steroid-resistant nephrotic syndrome
(no response to prednisone
60 mg m–2 day–1 within 4 weeks)
Proteinuria not suspicious for MCD
(no pretreatment with prednisone)
Biopsy Biopsy
No FSGS No FSGSFSGS FSGS




Consider gene testing, syndromatic FSGS?*
Positive for mutation in podocine,
WT1, CD2AP, TRPC6 and so on Not done, not available, negative
Careful watching, antiproteinuric 
treatment with ACE inhibitors, 
angiotensin receptor blocker* 
Trial with cyclosporin, 
concomitant prednisone 
for at least 6 months
Continue cyclosporin 
as long-term treatment*
Rule out other underlying diseases 
leading to FSGS*
Figure 3 | Algorithm for the use of cyclosporin in the treatment of focal segmental glomerulosclerosis in children.
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discontinued, if possible before any change in cyclosporin.
Patients who achieve a partial remission should be main-
tained on the lowest dose of cyclosporin to maintain their
partial remission status with careful monitoring of the dose,
cyclosporin trough level (C0), and renal function. If no
response to cyclosporin has occurred after 6 months of
treatment (a minimum of 50% reduction in baseline
proteinuria), other agents should be considered or added to
cyclosporin (for example, cytotoxic agent or MPA).
Membranous nephropathy
Clinical background. Overview: Membranous nephropa-
thy rarely occurs in children. It is, however, the most
common cause of idiopathic nephrotic syndrome in adults
and accounts for approximately 20–30% of adult cases. The
disease is seen more frequently in men (male/female¼ 2–3:1)
and presents most commonly between the ages of 40 and 60.
The natural history of MGN is variable. Complete remission
occurs spontaneously in 20–30% of cases and is more likely to
occur in patients presenting with subnephrotic proteinuria
and in women.89 Approximately 20–40% of cases will have
persistent proteinuria between 3 and 5 g/day1 and the
remaining 40–50% will develop progressive renal failure.90
Prognosis might also be influenced by racial origin since
long-term outcome in the Asian population (Japanese) with
MGN is significantly better than Caucasians.91 Cattran et al.17
identified risk categories for the development of chronic renal
failure in MGN patients by stratifying cases according to the
severity of their proteinuria over a 6-month period; low-risk
patients were those with normal serum creatinine and
proteinuria consistently o4 g day1; medium-risk patients
had normal or nearly normal serum creatinine and
proteinuria consistently between 4 and 8 g day1; and high-
risk patients were those with abnormal and/or deteriorating
serum creatinine or proteinuria X8 g day1. This strategy
largely avoids treatment of the patients who are most likely to
spontaneously remit and/or have stable low-grade, subne-
phrotic proteinuria. Favorable renal outcome in MGN is
associated with complete or partial remission of proteinur-
ia.18,92 In addition to the risk of chronic renal failure, certain
extrarenal effects are more common in MGN, including
accelerated vascular disease and an increased risk of
thromboembolism.
Treatment options: A meta-analysis of randomized con-
trolled trials using corticosteroid therapy as a single agent
demonstrated no effect on renal survival or on the
probability of remission of proteinuria.90 A large, retro-
spective review from Japan did show a benefit on renal
survival following a 4-week course of corticosteroids. This
may reflect the influence of race on either MGN natural
history or on its therapeutic responsiveness in this racial
group.91 Cycling a cytotoxic agent with a corticosteroid over
a 6-month period has been shown to both reduce proteinuria
and slow disease progression.93,94 Ten-year follow-up data
demonstrated a renal survival of 92% in treated patients
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Accept partial remission if clinically beneficial 
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Figure 4 | Algorithm for the use of cyclosporin in the treatment of focal segmental glomerulosclerosis in adults.
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remission (complete or partial) was 83% for treated patients
versus only 38% for untreated patients.93 A similar result was
seen when this 6-month cycle used cyclophosphamide in
place of chlorambucil. Adverse effects, real or anticipated,
have somewhat limited the use of this regimen. Relapses rates
when this routine was used with either of the cytotoxic agent
approached 30–40% 2-3 years following discontinuation of
therapy.90,94 Mycophenolate, a relatively new immunosup-
pressive agent with less toxicity than cyclophosphamide is a
safer alternative but the current level of evidence supporting
it efficacy is still weak and relapse rates higher.95
Efficacy of cyclosporin in MGN: Cattran’s single-blind
clinical trial96 of 51 patients with steroid-resistant MGN
randomized to cyclosporin or placebo provides Level 1
evidence of its efficacy. Cyclosporin dose averaged
3.5 mg kg1 day1 given in two divided doses for 26 weeks;
the drug dose was then tapered to 0 over the next 4 weeks.
Prednisone was given to all patients at 0.15 mg kg1 day1 for
26 weeks and then tapered off over the next 6 weeks.
Remission (complete or partial) was obtained in 75%
of the treatment group versus only 22% of the placebo
group by 26 weeks (Po0.001). By the end of the obser-
vation period (78 weeks), 39% of the treatment group had
remained in remission versus 13% of the placebo group
(Po0.007). Renal function in the two groups remained
unchanged and equal throughout the trial and the follow-up
period.
A study by Alexopoulos et al.97 (Level 2) has shown that
prolonged treatment (412 months) with low-dose cyclos-
porin increases remission rates and that prolonged treatment
with low-dose cyclosporin 1.4–1.5 mg kg1 day1 is useful in
maintaining remission. Relapse occurred more frequently
when the daily dose of cyclosporin was lower
(1.0–1.1 mg kg1 day1) or the C0 cyclosporin levels de-
creased below 100 ng ml1. Patients who relapsed had a mean
C0 cyclosporin level of 72748 ng ml
1, compared to the
mean level in non-relapsers of 194780 ng ml1 (Po0.03).
Cyclosporin has also been studied in the high risk of
progression group. In a randomized controlled trial of
patients with documented progressive renal insufficiency
(mean creatinine was 195 mmol l1) and heavy proteinuria,
cyclosporin was administered at an average dose of
3.8 mg kg1, and compared to placebo alone over a 12-
month period.98 Cyclosporin-treated patients demonstrated
both significantly reduced proteinuria and a slower rate of
progression as measured by rate of change in the creatinine
clearance (P¼ 0.02, and Po0.02, respectively). These positive
results were sustained in more than half of the patients for up
to 2 years after treatment was stopped. However, the number
of patients in the study was small, there was a trend toward
transient increases in creatinine noted in the cyclosporin
treatment group and adverse effects were more common with
treatment than in studies where the renal function was
normal (Level 1).
A similar benefit was noted in an uncontrolled study of 15
individuals with steroid-resistant progressive disease, except
their relapse rate was higher99 (Level 4). A retrospective
review was reported from a large collaborative group
who treated 41 patients considered high risk due to the
severity of proteinuria (410 g day1) and resistance to other
immunosuppressive drugs.100 Thirty-four percent achieved a
complete remission after a median treatment duration of
353 days, at a mean cyclosporin dose of 3.3 mg kg1 day1
(Level 5).
Additional studies in MGN include cyclosporin treatment
given for 3-6 months at 4–5 mg kg1 day1. These authors
found a median reduction in proteinuria by more than 50%
in 41 MGN patients.23 The majority of remitters relapsed
following drug cessation but subsequently remitted upon
restarting cyclosporin (Level 5).
In another small study, eight MGN patients with
refractory nephrotic syndrome received cyclosporin with
the dose adjusted to achieve a C0 (trough) level of
100 ng ml1 for 3 months, then maintained at a C0 of
50 ng ml.101 At 12 months, five out of eight patients (63%)
showed complete or partial remission, and this increased to
seven out of eight patients (88%) at 18 months. No changes
in renal function or blood pressure occurred (Level 5).
MGN is uncommon in children with the only data
suggesting a similar response as in adults but the numbers
were very small (Level 6).102
In summary, current data indicate that cyclosporin is
effective in inducing a partial or complete remission of
proteinuria between 60 and 75% of MGN cases.96,101 The
time to maximum reduction of proteinuria was commonly
beyond 3 months of treatment, similar to the cytotoxic/
steroid regimens. (See also Table 5 for a summary of study
details.)
Tolerability of cyclosporin in MGN: The risk of adverse
events with cyclosporin in MGN is similar to that observed in
adults with MCD or FSGS.64 The risk of nephrotoxicity in
MGN appears to be low if guidelines on cyclosporin dosing
are followed.64 In Cattran’s study,96 the incidence and severity
of hypertension was increased in patients receiving cyclos-
porin compared to those on placebo. Additional side effects
of cyclosporin (gum hyperplasia and hypertrichosis) have
also been reported in this patient population.101
Treatment guidelines and algorithm for use of cyclosporin in
membranous nephropathy. See Figure 5 for full details.
Who to treat? Patients with MGN should first be assessed
with regard to their risk of progression (see above). Patients
characterized as low risk may be treated only symptomati-
cally, using ACE inhibitors and/or ARB drugs targeting a
blood pressure ofp120/75 mm Hg. They should continue to
be monitored for signs of renal function deterioration or
changes in severity of proteinuria. Treatment of medium-
and high-risk patients should be considered with either (i)
cyclosporin (7low-dose corticosteroids) for at least 6
months [Grade A] or (ii) cytotoxic (cyclophosomide or
chlorambucil) therapy alternating monthly with corticoster-
oids, composed of 1 g pulses of methylprednisolone daily for
the first 3 days followed by oral prednisone therapy at
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Table 5 | Cyclosporin studies in membranous nephropathy




n=28 CsA CsA 3.5 mg kg1 day1 given in two
divided doses 26 weeks, then
tapered to zero over 4 weeks
Remission in 75% (21/28) CsA
group versus 22% (5/23) Placebo
group by week 26 (Po0.001)
Steroid-resistant MN
with NS
n=28 Placebo All patients received Pred
0.15 mg kg1 day1 26 weeks,
then tapered over 8 weeks
By week 78, remission in 39% (11/
28) CsA group versus 13% (3/23)
Placebo group (P=0.007)
CsA versus Placebo Renal function remained
unchanged and equal in both
groups over the test medication
period
Number of cases and severity of
hypertension greater in CsA group
Cattran98 Randomized, controlled n=9 CsA CsA 3.5 mg kg1 day1 given in two
divided doses 12 months
CsA significantly reduced rate of
renal deterioration after 12 months
and this was maintained in 6/8 CsA
patients over a follow-up of (mean)
21 months
Progressive MN n=8 Placebo Vehicle control CsA group: Hypertension and






n=31 Pred+CsA Initial: Pred 0.6 mg kg1 day1 and/
or CsA 2–3 mg kg1 day1in two
divided doses for 12 months. Target
C0 levels 100–200 ng ml
1
Initial treatment: Similar remission
rates (CR+PR) in both groups (83
versus 85%, P=NS)
Biopsy proven MGN with
NS
n=20 CsA Long-term: Pred 0.1 mg kg1 day1
and CsA 1.0–1.5 mg kg1 day1 for
26716 months (n=26) versus CsA
1.0–1.5 mg kg1 day1 for 1978
months (n=17)
Long-term: More relapses in
monotherapy group (47 versus
15%, Po0.05) commonly in
patients with C0o100 ng ml1
Prednisolone+CsA
versus CsA alone
Effect of low dose CsA
Level 4 or 5
Ambalavanan23 Single-center, crossover n=41 in Phases 1 and
3 (of whom 14 in
Phase 2)
Phase 1: CsA 4–5 mg kg1 day1
given in two divided doses 3–6
months
Phase 1: CsA lowered median
proteinuria by 56% (Po0.0001)
Biopsy-proven MN Phase 2: CsA as above versus
Enalapril 10–30 mg day1; both 3
months
Phase 2: Enalapril had no effect on
proteinuria
CsA versus Enalapril Phase 3: CsA as above ( 6
months+1 month washout) 3
cycles
Phase 3: majority of patients
relapsed during each washout




n=8 CsA dose to maintain C0 at
100 ng ml1 during first 3 months,
then reduced to maintain C0 at
50 ng ml1 in patients attaining PR
and continued
PR or CR in 63% (5/8) after 12
months CsA therapy, rising to 88%
(7/8) after 18–24 months
Biopsy-proven MN,
refractory NS
All patients received Pred
10–40 mg day1 during first 3
months of CsA therapy, dose
tapered thereafter
One patient with gum hyperplasia
and hypertrichosis; no change in
renal function or BP




n=15 CsA 4–5 mg kg1 day1 15
months (median)
PR in 7/15 and CR in 4/15 and
further 4/15 had no response
Severe idiopathic MN
with NS
Responders: relapse of NS occurred
in 3/9 on drug cessation; further
two patients continued on CsA
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0.5 mg kg1 over a 6-month period [Grade A]. Which of
these should be the first-line treatment should be decided
following assessment of the individual patient for any specific
contraindications. A short course of corticosteroids alone
could be considered in the patient of Asian origin but the
evidence is not strong [Grade C].
Table 5 | Continued
Reference Study design Subjects Treatment Results
Effect of long-term, low-
dose CsA
Side effects were mild;
hypertension (n=3), renal
dysfunction (n=5)
Fritsche100 Retrospective case series n=41 CsA average dose
3.3 mg kg1 day1median
duration 353 days




CsA treatment durationo6 months
in 16/41 and 46 months in 25/41
Median treatment time to first CR
was 225 days
15/41 reported X1 adverse event;
commonly gingival hyperplasia
(n=4), nausea (n=4) and muscle
cramps (n=4); no correlation with
duration of treatment
CsA, cyclosporin; CR, complete remission; MN, membranous nephropathy; NS, nephrotic syndrome; PR, partial remission; Pred, predisone.
Partial remission 
Continue cyclosporin for at  
least 1–2 years 
If relapse, increase dose and
continue on cyclosporin
Assess risk of progression to ESRD 
Low risk
Normal renal function
Proteinuria  <4 g day–1
Medium risk
(despite maximum conservative therapy)
Normal renal function
Proteinuria  >4 g day–1 to <8 g day–1; observed for up to 6 months
High risk
(despite maximum conservative therapy)
Deteriorating renal function over 2–3 months±
Proteinuria  >8 g day–1 
ACE inhibitor±ARB





Cyclosporin±low-dose corticosteroid  
for at least 6 months (C0 125–200 ng ml–1) 
or cytotoxic + corticosteroid
Assess specific contra-indications
Cyclosporin±corticosteroid 
(C0 125–200 ng ml–1)
Cytotoxic + corticosteroid 
Complete remission
Taper cyclosporin dose over
at least 2–4 months
Continue to monitor
Response obtained but with
accompanying SAE
Alternative treatment required
Failure or relapse 
No response †







cytotoxic + corticosteroid at
reduced dose
Cyclosporin± low-dose corticosteroid  
for at least 6 months (C0 125–200 ng ml–1)
or cytotoxic + corticosteroid
Assess specific contra-indications
Figure 5 | Algorithm for the use of cyclosporin in the treatment of membranous nephropathy.
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When to treat? Patients with persistent nephrotic range
proteinuria and/or deteriorating renal function despite
maximum conservative therapy.
How to treat? Cyclosporin should be given at an initial
dose of 3–4 mg kg1 day1 with progressive reduction to the
smallest effective dose (b.i.d. dosing) for at least 6 months. If
proteinuria is not reduced by 50% by the end of this time
frame, cyclosporin should be discontinued and an alternative
therapy should be considered.
What to target? Treatment targets include complete or
partial remission of proteinuria, maintenance of stable GFR
(720% of pretreatment level), avoiding hypertension, and a
cyclosporin level regarded as non-toxic (C0¼ 125–175 ng ml1
and C2¼ 400–600 ng ml1).103
When to stop treatment? If complete remission occurs,
cyclosporin should be tapered off over 3-4 months. For
partial remission, cyclosporin should be continued at full
dose for an additional 1-2 years and perhaps maintained at a
non-toxic level indefinitely if renal function is stable in the
patient where a partial remission was difficult to achieve and/
or associated with additional morbidity and/or the patient
has previously failed alternate forms of treatment, or
alternatively cyclosporin could be slowly tapered slowly over
1-3 years and adjusted as required if proteinuria worsens
during the taper.
If there is no response to cyclosporin or if a response
occurs but with significant adverse effects, an alternative
therapeutic regimen (that is, cytotoxic agentþ corticosteroid)
should be considered.
CONCLUSIONS
Cyclosporin is an effective treatment for the three leading
histologic variants known to result in the idiopathic nephrotic
syndrome of adults and children. Recent Grade A evidence
supports its use after a 12-week course of cytotoxic therapy has
failed in MCD and as a first-line option in MGN and FSGS
either as monotherapy or in combination with corticosteroids.
Cyclosporin therapy provides a sustained remission of
proteinuria in a significant proportion of patients and is also
effective in the long-term preservation of renal function in
steroid-dependent/-resistant MCD and steroid-resistant FSGS.
The side-effect profile of cyclosporin is well known and
predictable. Adherence to dosing guidelines plus regular patient
monitoring will minimize the risk of nephrotoxicity, the major
concern of nephrologists caring for these patients.
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